Target intelligence / Profile preview

Acid phosphatase 4 (ACP4)

Target
ACP4
Molecular classification
Enzyme, Acid phosphatase, Protein tyrosine phosphatase, Integral membrane protein
01

Overview

Acid phosphatase 4 (ACP4) is an integral membrane enzyme belonging to the histidine acid phosphatase family, with structural similarity to prostatic and lysosomal acid phosphatases[1][6]. It exhibits protein tyrosine phosphatase activity and binds receptor tyrosine kinases, notably ERBB4, where it may regulate their cleavage and signaling[2][4][7]. ACP4 is predominantly expressed in secretory-stage ameloblasts during tooth development, where it is essential for proper enamel formation—mutations in ACP4 cause hypoplastic amelogenesis imperfecta, characterized by thin and poorly mineralized enamel[1]. While its principal physiological role is in odontogenesis, ACP4's exact substrates, apart from possibly the ERBB4 receptor, remain insufficiently characterized in humans[2][7]. There are currently no known approved drugs selectively targeting ACP4, and its clinical significance is primarily in genetic and dental disorders rather than as a therapeutic target[1][2][6][7].

Other names
Testicular acid phosphataseACPTAI1JAcid phosphatase, testicular
02

Mechanism of action

For inhibitors of acid phosphatase enzymes in general: Inhibition of phosphate monoester hydrolysis\n- No specific approved drugs targeting ACP4 are reported in the search results or primary literature

03

Biological functions

Hydrolysis of phosphate monoesters in acidic mediumProtein tyrosine dephosphorylationRegulation of enamel matrix protein processing and mineralization in amelogenesisNegative regulation of ERBB4 signaling pathwayReceptor tyrosine kinase bindingOdontogenesis (tooth development)
04

Disease associations

Amelogenesis imperfecta (hypoplastic, non-syndromic)Enamel developmental disorders
05

Safety considerations

No therapeutic agents targeting ACP4 are reported; thus, no established safety profileTargeting ACP4 may affect enamel formation and tooth development, if delivered systemically or during tooth development
06

Biomarkers

Loss-of-function or pathogenic mutations in ACP4 serve as biomarkers for hypoplastic amelogenesis imperfecta

Beyond the preview

Go deeper on Acid phosphatase 4 (ACP4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acid phosphatase 4 (ACP4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call